FDA requires opioid labeling changes to help providers safely taper dosing
The Food and Drug Administration yesterday changes to the prescribing information included in outpatient opioid pain medication labels to provide expanded guidance to health care professionals on how to safely decrease or discontinue these medications in patients who are physically dependent on them. The agency said it has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased, a safety concern it continues to track.
Related News Articles
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…
Headline
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to…
Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
As the House Energy and Commerce Committee works to reauthorize key programs within the Substance Use-Disorder Prevention that Promotes Opioid Recovery and…